Go Pro
→ My top 3 AI picks for the next decade (From The Oxford Club) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
$5.17
+1.4%		$5.26
$2.40
▼
$16.34
$189.63M1.3108,679 shs67,744 shs
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
$4.27
-1.4%		$4.12
$3.03
▼
$7.97
$631.14M1.451.57 million shs846,656 shs
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
$6.47
$6.47
$5.73
▼
$8.75
$644.66M0.79N/AN/A
Valneva SE Sponsored ADR stock logo
VALN
Valneva
$6.75
-3.0%		$5.43
$4.75
▼
$12.23
$660.40M1.77183,379 shs21,945 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
+1.37%+15.40%+10.94%-36.72%+92.91%
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
-1.39%+1.91%+1.67%+16.35%-41.59%
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
0.00%0.00%0.00%0.00%0.00%
Valneva SE Sponsored ADR stock logo
VALN
Valneva
-3.02%-4.39%+41.21%+11.57%-42.01%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
$5.17
+1.4%		$5.26
$2.40
▼
$16.34
$189.63M1.3108,679 shs67,744 shs
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
$4.27
-1.4%		$4.12
$3.03
▼
$7.97
$631.14M1.451.57 million shs846,656 shs
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
$6.47
$6.47
$5.73
▼
$8.75
$644.66M0.79N/AN/A
Valneva SE Sponsored ADR stock logo
VALN
Valneva
$6.75
-3.0%		$5.43
$4.75
▼
$12.23
$660.40M1.77183,379 shs21,945 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
+1.37%+15.40%+10.94%-36.72%+92.91%
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
-1.39%+1.91%+1.67%+16.35%-41.59%
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
0.00%0.00%0.00%0.00%0.00%
Valneva SE Sponsored ADR stock logo
VALN
Valneva
-3.02%-4.39%+41.21%+11.57%-42.01%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
2.67
Moderate Buy$15.00190.14% Upside
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
2.71
Moderate Buy$8.4397.39% Upside
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
0.00
N/AN/AN/A
Valneva SE Sponsored ADR stock logo
VALN
Valneva
2.00
Hold$9.3037.78% Upside

Current Analyst Ratings Breakdown

Latest ARMP, VALN, SVA, and MDXG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/17/2026
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$8.00
8/17/2026
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$8.00
8/13/2026
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
8/11/2026
Valneva SE Sponsored ADR stock logo
VALN
Valneva
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$12.00
8/11/2026
Valneva SE Sponsored ADR stock logo
VALN
Valneva
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$12.00
6/18/2026
Valneva SE Sponsored ADR stock logo
VALN
Valneva
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 8/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
$4.90M39.23N/AN/A($6.00) per share-0.86
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
$418.63M1.49$0.55 per share7.82$1.73 per share2.47
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
$386.01M1.67$0.54 per share11.89$89.01 per share0.07
Valneva SE Sponsored ADR stock logo
VALN
Valneva
$197.56M3.24N/AN/A$1.39 per share4.86
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
-$173.80M-$1.64N/AN/AN/A-3,467.04%-12.24%32.16%11/11/2026 (Estimated)
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
$48.58M$0.04106.7825.12N/A1.76%12.09%9.22%11/4/2026 (Estimated)
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
-$59.68MN/AN/AN/AN/AN/AN/AN/AN/A
Valneva SE Sponsored ADR stock logo
VALN
Valneva
-$130.33M-$2.11N/A15.34N/A-110.33%-153.20%-39.50%N/A

Latest ARMP, VALN, SVA, and MDXG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Valneva SE Sponsored ADR stock logo
VALN
Valneva
-$0.1886-$0.40-$0.2114-$0.38$44.17 million$39.37 million
8/12/2026Q2 2026
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
-$0.4450-$0.27+$0.1750-$0.27$0.40 million$2.51 million
7/29/2026Q2 2026 & M&A announcement
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
-$0.0495-$0.05-$0.0005-$0.10$63.46 million$64.36 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
N/AN/AN/AN/AN/A
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
N/AN/AN/AN/AN/A
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
N/AN/AN/AN/AN/A
Valneva SE Sponsored ADR stock logo
VALN
Valneva
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
N/A
0.11
0.11
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
0.07
5.33
4.79
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
0.04
6.07
5.97
Valneva SE Sponsored ADR stock logo
VALN
Valneva
2.04
2.16
1.69

Institutional Ownership

CompanyInstitutional Ownership
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
3.57%
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
79.15%
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
N/A
Valneva SE Sponsored ADR stock logo
VALN
Valneva
11.39%

Insider Ownership

CompanyInsider Ownership
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
84.50%
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
2.50%
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
12.79%
Valneva SE Sponsored ADR stock logo
VALN
Valneva
14.91%
CompanyEmployeesShares OutstandingFree FloatOptionable
Armata Pharmaceuticals, Inc. stock logo
ARMP
Armata Pharmaceuticals
7037.18 million5.76 millionNot Optionable
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
870145.76 million142.12 millionOptionable
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
3,00899.64 million86.89 millionOptionable
Valneva SE Sponsored ADR stock logo
VALN
Valneva
70094.89 million80.74 millionNot Optionable

Recent News About These Companies

Valneva's Regulatory Tailwind Collides With a Deepening Loss Profile
August 24 at 10:06 PM  |  ad-hoc-news.deA
Valneva (NASDAQ:VALN) Shares Gap Down - Here's Why
August 24 at 11:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/valneva-nasdaqvaln-shares-gap-down-heres-why-2026-08-24/
Valneva's Analyst Divide Widens as EMA Review Puts Statistical Questions in the Spotlight
August 20, 2026  |  ad-hoc-news.deA
Valneva (VALN) Q2 2026 Earnings Call Transcript
August 20, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/valneva-valn-q2-2026-earnings-194457376.html
Research Analysts Issue Forecasts for Valneva Q3 Earnings
August 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/research-analysts-issue-forecasts-for-valneva-q3-earnings-2026-08-18/
EMA validates marketing authorisation application of Pfizer & Valneva’s PF-07307405, a 6-valent OspA-based Lyme disease vaccine
August 17, 2026  |  pharmabiz.comP
EMA validates Pfizer and Valneva’s Lyme disease vaccine
August 17, 2026  |  msn.comhttps://www.msn.com/en-us/health/medical/ema-validates-pfizer-and-valneva-s-lyme-disease-vaccine/ar-AA2ajQPm
Pfizer, Valneva Lyme vaccine starts review in Europe
August 15, 2026  |  pharmaphorum.comP
Valneva Shares Climb After Lyme Disease Vaccine Receives EMA Application Acceptance
August 15, 2026  |  marketwatch.comhttps://www.marketwatch.com/story/valneva-shares-climb-after-lyme-disease-vaccine-receives-ema-application-acceptance-8a143cc5
Update: Valneva Shares Gain as Lyme Vaccine Candidate Gets EMA Review
August 15, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/valneva-shares-gain-lyme-vaccine-112557623.html
Valneva (NASDAQ:VALN) Issues Earnings Results, Misses Expectations By $0.17 EPS
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/valneva-nasdaqvaln-issues-earnings-results-misses-expectations-by-017-eps-2026-08-14/
Valneva (NASDAQ:VALN) Sees Strong Trading Volume - What's Next?
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/valneva-nasdaqvaln-sees-strong-trading-volume-whats-next-2026-08-14/
A Lyme disease vaccine may finally be on the way. Why did it take so long?
August 14, 2026  |  nationalpost.comN
EU to study potential vaccine for Lyme disease: companies
August 14, 2026  |  yahoo.comhttps://www.yahoo.com/news/science/articles/eu-study-potential-vaccine-lyme-083842023.html
Valneva SE 2026 Q2 - Results - Earnings Call Presentation
August 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4936632-valneva-se-2026-q2-results-earnings-call-presentation
Valneva (NASDAQ:VALN) Research Coverage Started at TD Cowen
August 14, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30959420
Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
August 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/14/3345081/0/en/pfizer-and-valneva-s-lyme-disease-vaccine-candidate-marketing-authorization-application-validated-by-european-medicines-agency.html
Valneva SE (INRLF) (H1 2026) Earnings Call Highlights: Strategic Pivot and Lyme Vaccine ...
August 13, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/valneva-se-inrlf-h1-2026-230543605.html
Valneva outlines $145M-$160M 2026 revenue guidance while Pfizer targets Lyme decisions within 12 months
August 13, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4632961-valneva-outlines-145m-160m-2026-revenue-guidance-while-pfizer-targets-lyme-decisions-within
Valneva SE (VALN) Q2 2026 Earnings Call Transcript
August 13, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4936454-valneva-se-valn-q2-2026-earnings-call-transcript
Valneva Q2 Earnings Call Highlights
August 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/valneva-q2-earnings-call-highlights-2026-08-13/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Armata Pharmaceuticals stock logo

Armata Pharmaceuticals NYSEAMERICAN:ARMP

$5.17 +0.07 (+1.37%)
Closing price 08/24/2026 04:10 PM Eastern
Extended Trading
$5.12 -0.04 (-0.87%)
As of 08/24/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.

MiMedx Group stock logo

MiMedx Group NASDAQ:MDXG

$4.27 -0.06 (-1.39%)
Closing price 08/24/2026 04:00 PM Eastern
Extended Trading
$4.28 +0.01 (+0.12%)
As of 08/24/2026 06:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

Sinovac Biotech stock logo

Sinovac Biotech NASDAQ:SVA

$6.47 0.00 (0.00%)
As of 08/21/2026

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.

Valneva stock logo

Valneva NASDAQ:VALN

$6.75 -0.21 (-3.02%)
Closing price 08/24/2026 04:00 PM Eastern
Extended Trading
$6.76 +0.00 (+0.07%)
As of 08/24/2026 05:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas